



Adzenys ER™ (amphetamine) – First-time authorized brand alternative

- On December 23, 2019, Prasco launched an authorized brand alternative of Neos Therapeutics' [Adzenys ER \(amphetamine\)](#) extended-release oral suspension.
- Adzenys ER is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.
- Adzenys is also available as a brand extended-release orally-disintegrating tablet ([Adzenys XR-ODT™](#)) that carries the same indication as Adzenys ER.
- Adzenys ER carries a boxed warning for abuse and dependence.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.